HEALTHCARE TRIANGLE INC (HCTI) Fundamental Analysis & Valuation
NASDAQ:HCTI • US42227W4050
Current stock price
2.47 USD
-0.07 (-2.76%)
At close:
2.3901 USD
-0.08 (-3.23%)
After Hours:
This HCTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HCTI Profitability Analysis
1.1 Basic Checks
- HCTI had negative earnings in the past year.
- HCTI had a negative operating cash flow in the past year.
- In the past 5 years HCTI reported 4 times negative net income.
- HCTI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- HCTI's Return On Assets of -45.69% is on the low side compared to the rest of the industry. HCTI is outperformed by 65.71% of its industry peers.
- Looking at the Return On Equity, with a value of -72.30%, HCTI is doing worse than 68.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.69% | ||
| ROE | -72.3% | ||
| ROIC | N/A |
ROA(3y)-159.11%
ROA(5y)-96.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 13.11%, HCTI is doing worse than 88.57% of the companies in the same industry.
- In the last couple of years the Gross Margin of HCTI has grown nicely.
- The Profit Margin and Operating Margin are not available for HCTI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.08%
GM growth 5Y3.95%
2. HCTI Health Analysis
2.1 Basic Checks
- HCTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for HCTI has been increased compared to 1 year ago.
- HCTI has more shares outstanding than it did 5 years ago.
- HCTI has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -3.67, we must say that HCTI is in the distress zone and has some risk of bankruptcy.
- HCTI's Altman-Z score of -3.67 is on the low side compared to the rest of the industry. HCTI is outperformed by 71.43% of its industry peers.
- HCTI has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
- HCTI has a worse Debt to Equity ratio (0.17) than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.67 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
- A Current Ratio of 2.03 indicates that HCTI has no problem at all paying its short term obligations.
- HCTI's Current ratio of 2.03 is in line compared to the rest of the industry. HCTI outperforms 54.29% of its industry peers.
- HCTI has a Quick Ratio of 1.98. This is a normal value and indicates that HCTI is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.98, HCTI is in line with its industry, outperforming 54.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.03 | ||
| Quick Ratio | 1.98 |
3. HCTI Growth Analysis
3.1 Past
- HCTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.51%, which is quite impressive.
- The Revenue for HCTI has decreased by -21.88% in the past year. This is quite bad
- The Revenue for HCTI have been decreasing by -16.46% on average. This is quite bad
EPS 1Y (TTM)81.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.22%
Revenue 1Y (TTM)-21.88%
Revenue growth 3Y-30.78%
Revenue growth 5Y-16.46%
Sales Q2Q%44.59%
3.2 Future
- The Earnings Per Share is expected to grow by 43.35% on average over the next years. This is a very strong growth
- The Revenue is expected to decrease by -12.97% on average over the next years. This is quite bad
EPS Next Y-203233.33%
EPS Next 2Y-2326.7%
EPS Next 3Y-525.26%
EPS Next 5Y43.35%
Revenue Next Year-72.5%
Revenue Next 2Y-36.88%
Revenue Next 3Y-21.81%
Revenue Next 5Y-12.97%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. HCTI Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for HCTI. In the last year negative earnings were reported.
- Also next year HCTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- HCTI's earnings are expected to decrease with -525.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2326.7%
EPS Next 3Y-525.26%
5. HCTI Dividend Analysis
5.1 Amount
- HCTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
HCTI Fundamentals: All Metrics, Ratios and Statistics
2.47
-0.07 (-2.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners1.53%
Inst Owner Change-100%
Ins OwnersN/A
Ins Owner Change0%
Market Cap2.87M
Revenue(TTM)12.94M
Net Income(TTM)-6.32M
Analysts82.86
Price Target306 (12288.66%)
Short Float %8.85%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5900%
EPS NY rev (1m)-9900%
EPS NY rev (3m)-9900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.33 | ||
| P/tB | 1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6183.86
EYN/A
EPS(NY)-54.06
Fwd EYN/A
FCF(TTM)-10.16
FCFYN/A
OCF(TTM)-9.05
OCFYN/A
SpS11.16
BVpS7.54
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.69% | ||
| ROE | -72.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.11% | ||
| FCFM | N/A |
ROA(3y)-159.11%
ROA(5y)-96.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.08%
GM growth 5Y3.95%
F-Score3
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.03 | ||
| Quick Ratio | 1.98 | ||
| Altman-Z | -3.67 |
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.22%
EPS Next Y-203233.33%
EPS Next 2Y-2326.7%
EPS Next 3Y-525.26%
EPS Next 5Y43.35%
Revenue 1Y (TTM)-21.88%
Revenue growth 3Y-30.78%
Revenue growth 5Y-16.46%
Sales Q2Q%44.59%
Revenue Next Year-72.5%
Revenue Next 2Y-36.88%
Revenue Next 3Y-21.81%
Revenue Next 5Y-12.97%
EBIT growth 1Y36.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-132.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.51%
OCF growth 3YN/A
OCF growth 5YN/A
HEALTHCARE TRIANGLE INC / HCTI Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for HEALTHCARE TRIANGLE INC?
ChartMill assigns a fundamental rating of 1 / 10 to HCTI.
Can you provide the valuation status for HEALTHCARE TRIANGLE INC?
ChartMill assigns a valuation rating of 0 / 10 to HEALTHCARE TRIANGLE INC (HCTI). This can be considered as Overvalued.
Can you provide the profitability details for HEALTHCARE TRIANGLE INC?
HEALTHCARE TRIANGLE INC (HCTI) has a profitability rating of 1 / 10.